Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 14, 2014, Pages 1472-1479

  Chien, A Jo ^a,b   Munster, Pamela N ^a,b   Melisko, Michelle E ^a,b   Rugo, Hope S ^a,b   Park, John W ^a,b   Goga, Andrei ^a,b   Auerback, Glenna ^a,b   Khanafshar, Elham ^a,b   Ordovas, Karen ^b   Koch, Kevin M ^c   Moasser, Mark M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENOXYLATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KETOCONAZOLE; LAPATINIB; LOPERAMIDE; OCTREOTIDE; ONDANSETRON; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER THERAPY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; FATIGUE; FEMALE; FOOD; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE; VOMITING; BLOOD; BREAST TUMOR; DOSE RESPONSE; GENETICS; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 84902822439     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.1161     Document Type: Article

References (31)

1. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002 (Pubitemid 34815868)
2. Jänne PA, Johnson BE: Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12:4416s-4420s, 2006 (Pubitemid 44197191)
3. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003 (Pubitemid 37297756)
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
6. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
7. Burstein HJ, Storniolo AM, Franco S, et al: A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068-1074, 2008 (Pubitemid 351796331)
8. Toi M, Iwata H, Fujiwara Y, et al: Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676-1682, 2009
9. Spector NL, Xia W, Burris H 3rd, et al: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512, 2005 (Pubitemid 47050840)
10. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
11. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
12. Karaman MW, Herrgard S, Treiber DK, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132, 2008
13. Rusnak DW, Lackey K, Affleck K, et al: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94, 2001
14. Wood ER, Truesdale AT, McDonald OB, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659, 2004 (Pubitemid 39297926)
15. Shan Y, Eastwood MP, Zhang X, et al: Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149:860-870, 2012
16. Burris HA 3rd, Taylor CW, Jones SF, et al: A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15:6702-6708, 2009
17. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
18. Holbro T, Beerli RR, Maurer F, et al: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938, 2003 (Pubitemid 36899201)
19. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68:5878-5887, 2008
20. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441, 2007 (Pubitemid 46160912)
21. Garrett JT, Olivares MG, Rinehart C, et al: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021-5026, 2011
22. Amin DN, Sergina N, Ahuja D, et al: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2:16ra7, 2010
23. Koch KM, Reddy NJ, Cohen RB, et al: Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 27:1191-1196, 2009
24. Smith DA, Koch KM, Arya N, et al: Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 67:421-426, 2009
25. Hsieh S, Tobien T, Koch K, et al: Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18:285-292, 2004 (Pubitemid 38166100)
26. Wang AZ: Giving failed drugs a fresh chance: A new direction for nanoparticle drug delivery. Expert Rev Med Devices 9:445-447, 2012
27. Stella VJ, Nti-Addae KW: Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 59:677-694, 2007 (Pubitemid 47285410)
28. Müller CE: Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem Biodivers 6:2071-2083, 2009
29. Fu Q, Sun J, Zhang W, et al: Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov 4:262-272, 2009
30. Al-Jamal WT, Kostarelos K: Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 44:1094-1104, 2011
31. Simon GR, Garrett CR, Olson SC, et al: Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: Results of a phase I pharmacokinetic study. Clin Cancer Res 12:4645-4651, 2006 (Pubitemid 44297817)